Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2011

01-04-2011 | Article

Calcineurin-dependent galactomannan release in Aspergillus fumigatus

Authors: M. A. S. H. Mennink-Kersten, D. Ruegebrink, P. E. Verweij, W. J. Steinbach

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2011

Login to get access

Abstract

The galactomannan assay to diagnose invasive aspergillosis is recommended and clinically utilized, yet the mechanism of galactomannan release from Aspergillus fumigatus is unknown. We used an A. fumigatus strain lacking calcineurin A (cnaA), already shown to be critically important for pathogenicity, to evaluate galactomannan kinetics. During the logarithmic growth phase when glucose was consumed, β-D-galactofuranoside (galf)-antigens were released in the culture. However, after glucose became limited, GM release further increased in the supernatants of the wild type strain while there was no further increase of GM release in the ΔcnaA strain. β-Galactofuranosidase activity was also decreased in the ΔcnaA mutant, and the amount of galf-antigen in the cell wall fraction of the ΔcnaA mutant was approximately ten-fold higher. This suggests the possibility that the antigen is unable to be released due to a cell wall abnormality. This and previous work suggest a dynamic calcineurin-dependent cell wall during periods of growth, with galactomannan release from the cell wall possibly calcineurin-dependent and reflected in the decreased GM release and greatly increased cell wall fraction of galf in the ΔcnaA mutant.
Literature
1.
go back to reference Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE (2006) In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1, 3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 44:1711–1718PubMedCrossRef Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE (2006) In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1, 3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 44:1711–1718PubMedCrossRef
2.
go back to reference Latge JP, Kobayashi H, Debeaupuis JP, Diaquin M, Sarfati J, Wieruszeski JM, Parra E, Bouchara JP, Fournet B (1994) Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 62:5424–5433PubMed Latge JP, Kobayashi H, Debeaupuis JP, Diaquin M, Sarfati J, Wieruszeski JM, Parra E, Bouchara JP, Fournet B (1994) Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 62:5424–5433PubMed
3.
go back to reference Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360PubMedCrossRef Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360PubMedCrossRef
4.
go back to reference Sarfati J, Boucias DG, Latgé JP (1995) Antigens of Aspergillus fumigatus produced in vivo. J Med Vet Mycol 33:9–14PubMedCrossRef Sarfati J, Boucias DG, Latgé JP (1995) Antigens of Aspergillus fumigatus produced in vivo. J Med Vet Mycol 33:9–14PubMedCrossRef
5.
go back to reference Steinbach WJ, Reedy JL, Cramer RA Jr, PJ R, Heitman J (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5:418–430PubMedCrossRef Steinbach WJ, Reedy JL, Cramer RA Jr, PJ R, Heitman J (2007) Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5:418–430PubMedCrossRef
6.
go back to reference Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR (2006) Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell 5:1091–1103PubMedCrossRef Steinbach WJ, Cramer RA Jr, Perfect BZ, Asfaw YG, Sauer TC, Najvar LK, Kirkpatrick WR, Patterson TF, Benjamin DK Jr, Heitman J, Perfect JR (2006) Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell 5:1091–1103PubMedCrossRef
7.
go back to reference Steinbach WJ, Cramer RAJ, Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR (2007) Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 51:2979–2981PubMedCrossRef Steinbach WJ, Cramer RAJ, Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR (2007) Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 51:2979–2981PubMedCrossRef
Metadata
Title
Calcineurin-dependent galactomannan release in Aspergillus fumigatus
Authors
M. A. S. H. Mennink-Kersten
D. Ruegebrink
P. E. Verweij
W. J. Steinbach
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2011
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-1118-5

Other articles of this Issue 4/2011

European Journal of Clinical Microbiology & Infectious Diseases 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine